{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:38:02Z","timestamp":1760056682715,"version":"build-2065373602"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010221","name":"Higher Education Commision, Pakistan","doi-asserted-by":"publisher","award":["21\u20131826\/SRGP\/R&D\/HEC\/2018"],"award-info":[{"award-number":["21\u20131826\/SRGP\/R&D\/HEC\/2018"]}],"id":[{"id":"10.13039\/501100010221","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03527-7","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:27:49Z","timestamp":1760012869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anticancer role of Gramicidin A in myeloid leukemia"],"prefix":"10.1007","volume":"16","author":[{"given":"Syeda","family":"Maham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mudassir","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleeha","family":"Noor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fazal","family":"Adnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salik Javed","family":"Kakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afsar Ali","family":"Mian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilawar","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"3527_CR1","doi-asserted-by":"publisher","unstructured":"Jimenez JJ, Chale RS, Abad AC, Schally AV. Acute promyelocytic leukemia (APL): a review of the literature, Oncotarget. 2020;11(11):992\u20131003. https:\/\/doi.org\/10.18632\/oncotarget.27513","DOI":"10.18632\/oncotarget.27513"},{"issue":"1","key":"3527_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.beha.2014.04.006","volume":"27","author":"F Lo-Coco","year":"2014","unstructured":"Lo-Coco F, Hasan SK. Understanding the molecular pathogenesis of acute promyelocytic leukemia. Best Pract Res Clin Haematol. 2014;27(1):3\u20139. https:\/\/doi.org\/10.1016\/j.beha.2014.04.006.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"3527_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"3527_CR4","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","volume":"21","author":"B Zhang","year":"2012","unstructured":"Zhang B, et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell. 2012;21(4):577\u201392. https:\/\/doi.org\/10.1016\/j.ccr.2012.02.018.","journal-title":"Cancer Cell"},{"issue":"6","key":"3527_CR5","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s12185-013-1354-4","volume":"97","author":"A Tomita","year":"2013","unstructured":"Tomita A, Kiyoi H, Naoe T. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in acute promyelocytic leukemia. Int J Hematol. 2013;97(6):717\u201325. https:\/\/doi.org\/10.1007\/s12185-013-1354-4.","journal-title":"Int J Hematol"},{"issue":"5","key":"3527_CR6","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/leu.2014.326","volume":"29","author":"AA Mian","year":"2015","unstructured":"Mian AA, et al. PF-114, a potent and selective inhibitor of native and mutated BCR\/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation. Leukemia. 2015;29(5):1104\u201314. https:\/\/doi.org\/10.1038\/leu.2014.326.","journal-title":"Leukemia"},{"key":"3527_CR7","doi-asserted-by":"publisher","unstructured":"Liu S et al. TXNRD1: a key regulator involved in the ferroptosis of CML cells induced by cysteine depletion in vitro. Oxid Med Cell Longev. 2021;2021(1). https:\/\/doi.org\/10.1155\/2021\/7674565","DOI":"10.1155\/2021\/7674565"},{"key":"3527_CR8","doi-asserted-by":"publisher","unstructured":"Liu J, et al. Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7(1). https:\/\/doi.org\/10.1038\/s41392-021-00762-6.","DOI":"10.1038\/s41392-021-00762-6"},{"issue":"5973","key":"3527_CR9","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1126\/science.1186624","volume":"327","author":"Y Wang","year":"2010","unstructured":"Wang Y, et al. The Wnt\/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010;327(5973):1650\u20133. https:\/\/doi.org\/10.1126\/science.1186624.","journal-title":"Science"},{"issue":"1","key":"3527_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.15586\/jkcvhl.2015.21","volume":"2","author":"JM David","year":"2015","unstructured":"David JM, Rajasekaran AK. Gramicidin A: A new mission for an old antibiotic. J Kidney Cancer VHL. 2015;2(1):15\u201324. https:\/\/doi.org\/10.15586\/jkcvhl.2015.21.","journal-title":"J Kidney Cancer VHL"},{"key":"3527_CR11","doi-asserted-by":"publisher","DOI":"10.3791\/50166","author":"BC Evans","year":"2013","unstructured":"Evans BC, et al. Ex vivo red blood cell hemolysis assay for the evaluation of pH-responsive endosomolytic agents for cytosolic delivery of biomacromolecular drugs. J Visualized Experiments. 2013;https:\/\/doi.org\/10.3791\/50166.","journal-title":"J Visualized Experiments"},{"key":"3527_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40880-016-0108-0","volume":"35","author":"Z-J Kang","year":"2016","unstructured":"Kang Z-J, et al. The Philadelphia chromosome in leukemogenesis. Chin J Cancer. 2016;35:48. https:\/\/doi.org\/10.1186\/s40880-016-0108-0.","journal-title":"Chin J Cancer"},{"issue":"1","key":"3527_CR13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1186\/s12885-021-08450-y","volume":"21","author":"M Fatima","year":"2021","unstructured":"Fatima M, Kakar SJ, Adnan F, Khan K, Mian AA, Khan D. AXL receptor tyrosine kinase: a possible therapeutic target in acute promyelocytic leukemia. BMC Cancer. 2021;21(1):713. https:\/\/doi.org\/10.1186\/s12885-021-08450-y.","journal-title":"BMC Cancer"},{"key":"3527_CR14","doi-asserted-by":"publisher","unstructured":"Dymond JS, Explanatory Chapter. 2013, pp. 279\u201389. https:\/\/doi.org\/10.1016\/B978-0-12-418687-3.00023-9","DOI":"10.1016\/B978-0-12-418687-3.00023-9"},{"issue":"1","key":"3527_CR15","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1186\/s12885-024-12958-4","volume":"24","author":"BB Nadeem","year":"2024","unstructured":"Nadeem BB, et al. Effects of imidazole derivatives on cellular proliferation and apoptosis in myeloid leukemia. BMC Cancer. 2024;24(1):1200. https:\/\/doi.org\/10.1186\/s12885-024-12958-4.","journal-title":"BMC Cancer"},{"issue":"1","key":"3527_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.15171\/bi.2015.01","volume":"5","author":"Y RahbarSaadat","year":"2017","unstructured":"RahbarSaadat Y, Saeidi N, Zununi Vahed S, Barzegari A, Barar J. An update to DNA ladder assay for apoptosis detection. BioImpacts. 2017;5(1):25\u20138. https:\/\/doi.org\/10.15171\/bi.2015.01.","journal-title":"BioImpacts"},{"key":"3527_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.tiv.2019.05.004","volume":"60","author":"M Tyagi","year":"2019","unstructured":"Tyagi M, Patro BS. Salinomycin reduces growth, proliferation and metastasis of cisplatin resistant breast cancer cells via NF-kB deregulation. Toxicol in Vitro. 2019;60:125\u201333. https:\/\/doi.org\/10.1016\/j.tiv.2019.05.004.","journal-title":"Toxicol in Vitro"},{"issue":"5","key":"3527_CR18","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1248\/bpb.b22-00674","volume":"46","author":"M Imai","year":"2023","unstructured":"Imai M, Izumisawa T, Saito D, Hasegawa S, Yamasaki M, Takahashi N. Effects of antibacterial agents on cancerous cell proliferation. Biol Pharm Bull. 2023;46(5):661\u201371. https:\/\/doi.org\/10.1248\/bpb.b22-00674.","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"3527_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3892\/ol.2016.5524","volume":"13","author":"G Jin","year":"2017","unstructured":"Jin G, et al. Expression of Axl and its prognostic significance in human breast cancer. Oncol Lett. 2017;13(2):621\u20138. https:\/\/doi.org\/10.3892\/ol.2016.5524.","journal-title":"Oncol Lett"},{"issue":"4","key":"3527_CR20","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.cell.2009.06.034","volume":"138","author":"PB Gupta","year":"2009","unstructured":"Gupta PB, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009;138(4):645\u201359. https:\/\/doi.org\/10.1016\/j.cell.2009.06.034.","journal-title":"Cell"},{"issue":"1","key":"3527_CR21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0092-8674(82)90409-3","volume":"31","author":"R Nusse","year":"1982","unstructured":"Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell. 1982;31(1):99\u2013109. https:\/\/doi.org\/10.1016\/0092-8674(82)90409-3.","journal-title":"Cell"},{"issue":"6","key":"3527_CR22","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","volume":"149","author":"H Clevers","year":"2012","unstructured":"Clevers H, Nusse R. Wnt\/\u03b2-Catenin signaling and disease. Cell. 2012;149(6):1192\u2013205. https:\/\/doi.org\/10.1016\/j.cell.2012.05.012.","journal-title":"Cell"},{"issue":"12","key":"3527_CR23","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1038\/emboj.2012.126","volume":"31","author":"P Polakis","year":"2012","unstructured":"Polakis P. Drugging Wnt signalling in cancer. EMBO J. 2012;31(12):2737\u201346. https:\/\/doi.org\/10.1038\/emboj.2012.126.","journal-title":"EMBO J"},{"issue":"1","key":"3527_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc3419","volume":"13","author":"JN Anastas","year":"2013","unstructured":"Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13(1):11\u201326. https:\/\/doi.org\/10.1038\/nrc3419.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"3527_CR25","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s12079-023-00773-8","volume":"17","author":"MLP Bueno","year":"2023","unstructured":"Bueno MLP, Saad STO, Roversi FM. The antitumor effects of WNT5A against hematological malignancies. J Cell Commun Signal. 2023;17(4):1487\u201399. https:\/\/doi.org\/10.1007\/s12079-023-00773-8.","journal-title":"J Cell Commun Signal"},{"key":"3527_CR26","doi-asserted-by":"publisher","first-page":"113599","DOI":"10.1016\/j.biopha.2022.113599","volume":"155","author":"MLP Bueno","year":"2022","unstructured":"Bueno MLP, Saad STO, Roversi FM. WNT5A in tumor development and progression: A comprehensive review. Biomed Pharmacother. 2022;155:113599. https:\/\/doi.org\/10.1016\/j.biopha.2022.113599.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"3527_CR27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semcancer.2006.07.014","volume":"16","author":"CV Dang","year":"2006","unstructured":"Dang CV, O\u2019Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol. 2006;16(4):253\u201364. https:\/\/doi.org\/10.1016\/j.semcancer.2006.07.014.","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"3527_CR28","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ccr.2009.12.045","volume":"17","author":"K Wang","year":"2010","unstructured":"Wang K, et al. PML\/RAR\u03b1 targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia. Cancer Cell. 2010;17(2):186\u201397. https:\/\/doi.org\/10.1016\/j.ccr.2009.12.045.","journal-title":"Cancer Cell"},{"key":"3527_CR29","doi-asserted-by":"publisher","unstructured":"Zhao Y-L, et al. Integrating CAR T-cell therapy and transplantation: comparisons of safety and long-term efficacy of allogeneic hematopoietic stem cell transplantation after CAR T-Cell or Chemotherapy-Based complete remission in B-Cell acute lymphoblastic leukemia. Front Immunol. 2021;12. https:\/\/doi.org\/10.3389\/fimmu.2021.605766.","DOI":"10.3389\/fimmu.2021.605766"},{"issue":"7","key":"3527_CR30","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1056\/NEJMoa040258","volume":"351","author":"CHM Jamieson","year":"2004","unstructured":"Jamieson CHM, et al. Granulocyte\u2013Macrophage progenitors as candidate leukemic stem cells in Blast-Crisis CML. N Engl J Med. 2004;351(7):657\u201367. https:\/\/doi.org\/10.1056\/NEJMoa040258.","journal-title":"N Engl J Med"},{"key":"3527_CR31","doi-asserted-by":"publisher","unstructured":"Huczynski A. Salinomycin \u2013 A new cancer drug candidate. Chem Biol Drug Des. Mar. 2012;79(3):235\u20138. https:\/\/doi.org\/10.1111\/j.1747-0285.2011.01287.x.","DOI":"10.1111\/j.1747-0285.2011.01287.x"},{"key":"3527_CR32","doi-asserted-by":"publisher","first-page":"950658","DOI":"10.1155\/2012\/950658","volume":"2012","author":"C Naujokat","year":"2012","unstructured":"Naujokat C, Steinhart R. Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol. 2012;2012:950658. https:\/\/doi.org\/10.1155\/2012\/950658.","journal-title":"J Biomed Biotechnol"},{"issue":"4","key":"3527_CR33","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2015.07.013","volume":"162","author":"HW Park","year":"2015","unstructured":"Park HW, et al. Alternative Wnt signaling activates YAP\/TAZ. Cell. 2015;162(4):780\u201394. https:\/\/doi.org\/10.1016\/j.cell.2015.07.013.","journal-title":"Cell"},{"issue":"1","key":"3527_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","volume":"17","author":"BT MacDonald","year":"2009","unstructured":"MacDonald BT, Tamai K, He X. Wnt\/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9\u201326. https:\/\/doi.org\/10.1016\/j.devcel.2009.06.016.","journal-title":"Dev Cell"},{"issue":"1","key":"3527_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/embo-reports\/kvd012","volume":"1","author":"A Hecht","year":"2000","unstructured":"Hecht A, Kemler R. Curbing the nuclear activities of beta-catenin. Control over Wnt target gene expression. EMBO Rep. 2000;1(1):24\u20138. https:\/\/doi.org\/10.1093\/embo-reports\/kvd012.","journal-title":"EMBO Rep"},{"issue":"1","key":"3527_CR36","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40364-022-00418-9","volume":"10","author":"S Yu","year":"2022","unstructured":"Yu S, Han R, Gan R. The Wnt\/\u03b2-catenin signalling pathway in haematological neoplasms. Biomark Res. 2022;10(1):74. https:\/\/doi.org\/10.1186\/s40364-022-00418-9.","journal-title":"Biomark Res"},{"issue":"2","key":"3527_CR37","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1517\/14728222.2014.978860","volume":"19","author":"MA Blevins","year":"2015","unstructured":"Blevins MA, Towers CG, Patrick AN, Zhao R, Ford HL. The SIX1-EYA transcriptional complex as a therapeutic target in cancer. Expert Opin Ther Targets. 2015;19(2):213\u201325. https:\/\/doi.org\/10.1517\/14728222.2014.978860.","journal-title":"Expert Opin Ther Targets"},{"issue":"6","key":"3527_CR38","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00467-012-2246-1","volume":"28","author":"P-X Xu","year":"2013","unstructured":"Xu P-X. The EYA-SO\/SIX complex in development and disease. Pediatr Nephrol. 2013;28(6):843\u201354. https:\/\/doi.org\/10.1007\/s00467-012-2246-1.","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"3527_CR39","doi-asserted-by":"publisher","first-page":"6815","DOI":"10.1128\/MCB.19.10.6815","volume":"19","author":"H Ohto","year":"1999","unstructured":"Ohto H, et al. Cooperation of six and Eya in activation of their target genes through nuclear translocation of Eya. Mol Cell Biol. 1999;19(10):6815\u201324. https:\/\/doi.org\/10.1128\/MCB.19.10.6815.","journal-title":"Mol Cell Biol"},{"key":"3527_CR40","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.2174\/15672050113109990199","volume":"20","author":"S Zhou","year":"2013","unstructured":"Zhou S, et al. Salinomycin: A novel Anti-Cancer agent with known Anti-Coccidial activities. Curr Med Chem. 2013;20:4095\u2013101. https:\/\/doi.org\/10.2174\/15672050113109990199.","journal-title":"Curr Med Chem"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03527-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03527-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03527-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:27:49Z","timestamp":1760012869000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03527-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3527"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03527-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"23 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the experimental protocols were approved by National University of Sciences and Technology (NUST) institutional review board, and the certificate has been received for \u201cDevelopment of drug-able CRISPR\/Cas9 for treating beta-Thalassemia and Sickle Cell Anemia\u201d. All the experiments were performed in accordance with relevant guidelines and regulations. An informed consent for participation of the outcomes was obtained prior to performing any procedure.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"An informed consent for publication of the outcomes was obtained prior to performing any procedure.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1839"}}